82594-80-7

Usage

Uses

Used in Organic Synthesis:
1-Triphenylmethyl-4-methylimidazole serves as a protecting group for alcohols and carboxylic acids, crucial in organic synthesis to prevent unwanted reactions at certain functional groups, thereby facilitating the selective formation of desired products.
Used in Catalysis and Coordination Chemistry:
Due to its ability to form stable complexes with metal ions, 1-Triphenylmethyl-4-methylimidazole is utilized in catalysis to enhance the efficiency of chemical reactions and in coordination chemistry to study and create new metal complexes with potential applications in various fields.
Used in Pharmaceutical Synthesis:
1-Triphenylmethyl-4-methylimidazole acts as a reagent in the synthesis of pharmaceuticals, contributing to the development of new drugs and improving the synthesis processes of existing ones.
Used in Advanced Materials and Biochemistry:
1-Triphenylmethyl-4-methylimidazole has been studied for its potential applications in creating advanced materials and is involved in biochemical research, indicating its broad utility across scientific disciplines.

InChI:InChI=1/C23H20N2/c1-19-17-25(18-24-19)23(20-11-5-2-6-12-20,21-13-7-3-8-14-21)22-15-9-4-10-16-22/h2-18H,1H3

Upstream product

• 822-36-6 4-methyl-1H-imidazole 
• 76-83-5 trityl chloride 

Downstream Products

• 5213-35-4 4-methyl-2-nitroimidazole 
• 211488-49-2 1-(4-Methyl-1-trityl-1H-imidazol-2-yl)-2-trityloxy-ethanol 
• 869967-21-5 4-methyl-1-(triphenylmethyl)-1H-imidazole-2-carbaldehyde 
• 144748-27-6 1-propyl-5-methylimidazole 
• 863399-36-4 4-methyl-1-(triphenylmethyl)-1H-imidazole-2-methanol 
• 1072452-34-6 1-trityl-3-[4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)butyl]-4-methyl-1H-imidazol-3-ium bromide 
• 1070654-62-4 1-trityl-3-[3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propyl]-4-methyl-1H-imidazol-3-ium bromide 
• 115383-28-3 4-methyl-3-phenacyl-1-triphenylmethylimidazolium bromide 

Relevant academic research and scientific papers

1,(3,)5-substituted imidazoles, useful in the treatment of hypertension and methods for their preparation

The present invention provides novel 1,5 and 1,3,5-substituted imidazole compounds in hydrophilic or lipophilic form, which are useful as angiotensin II ATI receptor antagonists suitable for transdermal delivery. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing compounds and their use in methods of treating hypertension and cardiovascular diseases.

Structure-activity relationship of human glutaminyl cyclase inhibitors having an N-(5-methyl-1H-imidazol-1-yl)propyl thiourea template

In an effort to design inhibitors of human glutaminyl cyclase (QC), we have synthesized a library of N-aryl N-(5-methyl-1H-imidazol-1-yl)propyl thioureas and investigated the contribution of the aryl region of these compounds to their structure-activity relationships as cyclase inhibitors. Our design was guided by the proposed binding mode of the preferred substrate for the cyclase. In this series, compound 52 was identified as the most potent QC inhibitor with an IC50 value of 58 nM, which was two-fold more potent than the previously reported lead 2. Compound 52 is a most promising candidate for future evaluation to monitor its ability to reduce the formation of pGlu-Aβ and Aβ plaques in cells and transgenic animals.

LRRK2 INHIBITORS

Provided herein are compounds that inhibit or partially inhibit the activity of leucine rich repeat kinases. Also provided herein are methods of treatment of CNS disorders comprising administration of inhibitors of leucine rich repeat kinases.

1,(3,)5-SUBSTITUTED IMIDAZOLES, THEIR USE IN THE TREATMENT OF HYPERTENSION AND METHODS FOR THEIR PREPARATION

The present invention provides novel 1,5 and 1,3,5-substituted imidazole compounds in hydrophilic or lipophilic form, which are useful as angiotensin II ATI receptor antagonists suitable for transdermal delivery. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing compounds and their use in methods of treating hypertension and cardiovascular diseases.

Synthesis, Biological Evaluation, and Molecular Modeling of 1 -Benzyl-1H-imidazoles as Selective Inhibitors of Aldosterone Synthase (CYP11B2)

Reducing aldosterone action is beneficial in various major diseases such as heart failure. Currently, this is achieved, with mineralocorticoid, receptor antagonists, however, aldosterone synthase (CYP 11B2) inhibitors may offer a promising alternative. In this study, we used three-dimensional modeling of CYP11B2 to model, the binding modes of the natural substrate 18-hydroxycorticosterone and the recently published CYP11B2 inhibitor R-fadrozole as a rational guide to design 44 structurally simple and achiral 1-benzyl-1H-imidazoles. Their syntheses, in vitro inhibitor potencies, and in silico docking are described. Some promising CYP11B2 inhibitors were identified, with our novel lead, MOERAS 115 (4-((5-phenyl-1H-imidazol-1-yl)methyl) benzonitrile) displaying an IC50 for CYP11B2 of 1.7 nM, and a CYP11B2 (versus CYP11B1) selectivity of 16.5, comparable to R-fadrozole (IC 50 for CYP11B26.0 nM, selectivity 19.8). Molecular docking of the inhibitors in the models enabled us to generate posthoc hypotheses on their binding modes, providing a valuable basis for future studies and further design of CYP11B2 inhibitors.

N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors

The invention relates to the use of a N-benzyl 5-substituted imidazole derivative having the general formula I wherein R is (C1-3)alkyl, (C1-3)alkyloxy, halogen, nitro or cyano; R1 is (C1-6)alkyl, optionally substituted with OH, (C1-3)alkyloxy, (C1-3)alkylcarbonyloxy, (C1-3)alkyloxycarbonyl or halogen, or (C1-3)alkyloxycarbonyl; or R1 is phenyl, optionally substituted with 1-3 substituents independently selected from (C1-3)alkyl, (C1-3)alkyloxy, hydroxylmethyl and halogen; or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of a disorder or disease in a subject mediated by aldosterone synthase or responsive to inhibition of aldosterone synthase.

Inhibitors for human glutaminyl cyclase by structure based design and bioisosteric replacement

The inhibition of human glutaminyl cyclase (hQC) has come into focus as a new potential approach for the treatment of Alzheimer's disease. The hallmark of this principle is the prevention of the formation of Aβ 3,11(pE)-40,42, as these Aβ-speci

NOVEL INHIBITORS OF GLUTAMINYL CYCLASE

Compounds of formula (I), combinations and uses thereof for disease therapy, or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein: A represents and B, R1, R2,

NOVEL INHIBITORS OF GLUTAMINYL CYCLASE

Compounds of formula (I), combinations and uses thereof for disease therapy, or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein: A represents and B, R1, R2,

NOVEL INHIBITORS OF GLUTAMINYL CYCLASE

Compounds of formula (I), combinations and uses thereof for disease therapy, or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein: R1 represents and R2, R